Ind-Swift Laboratories Limited has approved a capital investment of approximately ₹400 million (around ₹40 crore) to upgrade its finished dosage manufacturing facility in Samba, Jammu & Kashmir. The move marks a decisive step toward expanding its presence in regulated global markets.
The proposed upgrade will align the facility with international regulatory standards, primarily EU-GMP and PIC/S. Once completed, the enhanced plant will be positioned to serve key export destinations including Europe, the UK, Australia, Canada and South Africa. The company expects to complete the upgradation within 8–12 months and aims to secure EU-GMP approval within 8–9 months thereafter. It also plans to file around 15–20 molecules across multiple regulated markets simultaneously.
The Samba unit currently manufactures ointments for the domestic market, including own brands and contract manufacturing. Other dosage forms such as tablets, capsules and dry syrups are also produced at the facility. At present, the unit generates annual sales of about ₹360 million with an average bottom line of 10%.
Post-upgrade, Ind-Swift aims to significantly scale operations. From FY27–28 onwards, the company is targeting annual sales of ₹750–800 million from the facility, along with a stronger bottom line in the range of 18–20% of revenues. The infrastructure improvements are expected to enhance process robustness, reduce manual intervention, strengthen data integrity and ensure consistent high-quality output while improving environmental sustainability and utility reliability.
Commenting on the development, Sahil Munjal, Managing Director (Exports), highlighted rising demand in overseas markets and noted that the Jammu facility upgradation will support portfolio expansion across Europe, the UK, Australia and other regions, strengthening the company’s global footprint.
This upgrade comes as part of a broader strategic transformation. Following the ₹1,650 crore divestment of its API and CRAMS businesses and the subsequent merger with Ind-Swift Limited, the company is transitioning into a lean, net debt-free organisation focused on a pure-play formulations export and Contract Development & Manufacturing (CDM) platform.